These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30851267)

  • 1. Lessons Learned From Avastin and OCT-The Great, the Good, the Bad, and the Ugly: The LXXV Edward Jackson Memorial Lecture.
    Rosenfeld PJ
    Am J Ophthalmol; 2019 Aug; 204():26-45. PubMed ID: 30851267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).
    Chan CK; Jain A; Sadda S; Varshney N
    Trans Am Ophthalmol Soc; 2014 Jul; 112():160-98. PubMed ID: 25646034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How the comparison of age-related macular degeneration treatments trial results will impact clinical care.
    Davis J; Olsen TW; Stewart M; Sternberg P
    Am J Ophthalmol; 2011 Oct; 152(4):509-14. PubMed ID: 21961847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drusen Volume as a Predictor of Disease Progression in Patients With Late Age-Related Macular Degeneration in the Fellow Eye.
    Abdelfattah NS; Zhang H; Boyer DS; Rosenfeld PJ; Feuer WJ; Gregori G; Sadda SR
    Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1839-46. PubMed ID: 27082298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
    Shah AR; Del Priore LV
    Br J Ophthalmol; 2009 Aug; 93(8):1027-32. PubMed ID: 19429594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathologic Correlation of Anti-Vascular Endothelial Growth Factor-Treated Type 3 Neovascularization in Age-Related Macular Degeneration.
    Li M; Dolz-Marco R; Messinger JD; Wang L; Feist RM; Girkin CA; Gattoussi S; Ferrara D; Curcio CA; Freund KB
    Ophthalmology; 2018 Feb; 125(2):276-287. PubMed ID: 28964579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
    Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
    Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment
    Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC
    Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD.
    Waizel M; Todorova MG; Masyk M; Wolf K; Rickmann A; Helaiwa K; Blanke BR; Szurman P
    BMC Ophthalmol; 2017 May; 17(1):79. PubMed ID: 28535756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
    Cho H; Shah CP; Weber M; Heier JS
    Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration.
    Roller AB; Amaro MH
    Arq Bras Oftalmol; 2009; 72(5):677-81. PubMed ID: 20027409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study.
    Khurana RN; Chang LK; Bansal AS; Palmer JD; Wu C; Wieland MR
    Ophthalmol Retina; 2018 Feb; 2(2):128-133. PubMed ID: 31047339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of monthly and fortnightly anti-VEGF treatments for age-related macular degeneration.
    Nunes RP; Hirai FE; Barroso LF; Badaró E; Novais E; Rodrigues EB; Maia M; Magalhães O; Farah ME
    Arq Bras Oftalmol; 2019; 82(3):225-232. PubMed ID: 30810619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD].
    Moyal L; Cohen SY; Pedinielli A; Semoun O; Lalloum F; Jung C; Souied E
    J Fr Ophtalmol; 2015 Sep; 38(7):573-9. PubMed ID: 25997681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration.
    Forte R; Bonavolontà P; Benayoun Y; Adenis JP; Robert PY
    Ophthalmic Res; 2011; 45(3):129-34. PubMed ID: 20847575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol.
    Jørstad ØK; Faber RT; Moe MC
    Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.